Delcath Systems, Inc. is an interventional oncology company focused on the treatment of primary and metastatic liver cancers. The company's lead product, the HEPZATO KIT, is a drug/device combination product approved by the US Food and Drug Administration for the liver-directed treatment of adult patients with uveal melanoma with unresectable hepatic metastases. In Europe, the company markets the CHEMOSAT Hepatic Delivery System, a stand-alone medical device used for percutaneous hepatic perfusion to treat a range of liver cancers. Delcath Systems operates in the United States and Europe, serving interventional radiologists and medical centers treating patients with liver-dominant metastatic disease, including uveal melanoma, colorectal cancer, and hepatocellular carcinoma. The company was incorporated in 1988 and manages its supply chain through stockpiled inventory and multiple suppliers for critical components.

Summarised from the company's own disclosures, fiscal year ended Feb 2026

Industry Medical Devices Homepage delcath.com
Sector Healthcare IR page investors.delcath.com
Tags
interventional oncology, liver cancer, uveal melanoma, percutaneous hepatic perfusion, drug-device combination, hepatic delivery system, chemotherapy, metastatic disease, oncology, HEPZATO KIT, HEPZATO, CHEMOSAT, CHEMOSAT Hepatic Delivery System for Melphalan
Press page —

Metrics

Valuation  
Market cap $ 763.576M
Market cap (USD) $ 763.576M
P/E 137.25
PEG —
P/BV 5.72
P/S 6.94
P/OCF 33.21
P/FCF 37.97
Dividend yield —
Turnover / mcap —
Returns  
ROE 3.0%
ROI 3.9%
ROIC 0.74%
Profit margin 3.2%
Growth  
Revenue growing Yes
Profits growing Yes
Revenue up 3y No
Revenue up 5y —
Earnings growth 3y (net profit CAGR) —
Quality  
Profitable Yes
Margin expanding Yes
Buying back stock No
Diluting (TTM) No
Debt/Equity —
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 34
Quality score 0%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013 FY 2012 FY 2011 FY 2010 FY 2009 FY 2008 FY 2007 FY 2006
Revenue 85.231M 37.205M 2.065M 2.719M 1.3M — — 2.687M 2.715M 1.992M 1.747M 1.069M 790K 346K — — — — — —
Net profit 2.7M -26.386M -47.678M -36.508M -25.649M -24.156M -8.879M -19.222M -45.117M -17.971M -14.704M -17.381M -30.324M -51.868M -30.885M -46.684M — — — —
Free cash flow 20.969M -19.24M -31.309M -25.159M -22.747M -23.65M -23.714M -14.808M -15.922M -14.471M -16.59M -15.596M -34.244M -52.126M -39.979M -25.721M — — — —

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013 FY 2012 FY 2011 FY 2010 FY 2009 FY 2008 FY 2007 FY 2006
Share price 10.1 12.04 4.16 3.6 7.75 17.92 — 1.75 0.07 0.91 0.49 1.2 0.26 1.28 3.05 — 3.6 1.19 1.71 3.06
Price performance 12m -0.16 1.89 0.16 -0.54 -0.57 — — 24.58 -0.93 0.84 -0.59 3.68 -0.8 -0.58 — — 2.03 -0.3 -0.44 —

Filed figures

Figure Dec 2016 Dec 2017 Dec 2018 Dec 2019 Dec 2020 Dec 2021 Dec 2022 Dec 2023 Dec 2024 Dec 2025
Balance sheet detail
Trade receivables (USD) 403,000 317,000 585,000 21,000 57,000 44,000 366,000 241,000 10.9M 11.7M
↳ YoY growth +45.5% -21.3% +84.5% -96.4% +171.4% -22.8% +731.8% -34.2% +4,418.7% +7.8%
↳ 5y CAGR +17.1% +10.9% -34.5% -27.1% -35.8% +2.9% -16.3% +249.1% +190.3%
Lease liabilities (USD) — — 0.00 861,000 945,000 623,000 186,000 37,000 1.04M 936,000
Cash and deposits (USD) 4.41M 4M 2.52M 10M 28.6M 22.8M 7.67M 12.6M 32.4M 43.5M
Right-of-use assets (USD) — — 0.00 860,000 946,000 624,000 285,000 103,000 1.04M 936,000
Cash flow detail
Operating cash flow (USD) -14.2M -15.4M -14.7M -23.7M -22.9M -22.6M -25M -31.3M -18.7M 22.5M
Purchases of property, plant and equipment (USD) -258,000 -524,000 -76,000 -24,000 -782,000 -143,000 -209,000 -58,000 -559,000 -1.55M
Change in receivables (cash effect) (USD) -138,000 108,000 -293,000 497,000 -36,000 13,000 -322,000 125,000 -10.6M -854,000
Change in inventories (cash effect) (USD) 95,000 -543,000 385,000 204,000 -201,000 -557,000 -587,000 -1.32M -3.61M -3.32M
Change in payables (cash effect) (USD) 1.51M 3.18M 8.16M -4.79M -4.4M -1.14M 1.8M -199,000 479,000 4.77M
Share buybacks (cash effect) (USD) — — — — — — — — 0.00 -6M
Interest paid (cash effect) (USD) — — — 0.00 -11,000 -681,000 -1.87M -1.46M -1.24M 0.00
Income taxes paid (cash effect) (USD) — — — — — — — — 0.00 -1.55M
Share-based compensation (USD) — — — — — — 7.94M 8.15M 9.77M 24.2M
Operating cash flow before change in receivables (USD) -14.1M -15.5M -14.4M -24.2M -22.8M -22.6M -24.6M -31.4M -8.03M 23.4M
Free cash flow (OCF - PPE - intangibles) (USD) -14.5M -15.9M -14.8M -23.7M -23.7M -22.7M -25.2M -31.3M -19.2M 21M
Income detail
Research and development expense (USD) 8.45M 10.5M 19.7M 9.49M 11.2M 13.8M 18.6M 17.5M 13.9M 29.2M
↳ 5y CAGR -19.6% -16.7% +9.1% +17.2% +11.5% +10.3% +12.1% -2.3% +7.9% +21.2%
Total comprehensive income (USD) -18M -45M -19.2M -8.9M -24.3M -25.5M -36.4M -47.5M -26.4M 3.19M
Comprehensive income to owners (USD) -18M -45M -19.2M -8.9M -24.3M -25.5M -36.4M -47.5M -26.4M 3.19M
Reported Mar 29, 2017 Mar 16, 2018 Mar 25, 2020 Mar 31, 2021 Mar 31, 2021 Mar 31, 2022 Mar 26, 2024 Mar 26, 2024 Feb 26, 2026 Feb 26, 2026

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

Delcath Systems Reports Third Quarter 2026 Bull 6 Bear 0 Results

Results and Business Highlights

Increases 2026 Revenue Guidance to a Range of $115 million to $117 million

Conference Call Today at 8:30 a.m. Eastern Time

QUEENSBURY, NY – November 9, 2026, Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, today announced financial results and business highlights for the third quarter ended September 30, 2026.

Third Quarter 2026 Financial Results

•Total revenue of $35.1 million, compared with $20.6 million in the third quarter of 2025

◦HEPZATO KIT™ revenue of $32.7 million, compared to $19.3 million in the third quarter of 2025

◦CHEMOSAT® revenue of $2.4 million, compared to $1.3 million in the third quarter of 2025

•Gross margins of 89%, compared to 87% in the third quarter of 2025

•Net income of $7.0 million, compared to $0.8 million in the third quarter of 2025

•Non-GAAP adjusted EBITDA of $11.5 million, compared to $5.3 million in the third quarter of 2025

•Cash provided by operations of $8.2 million in the quarter; compared to $4.8 million in the third quarter of 2025

•Cash and investments of $104.3 million as of September 30, 2026; and no debt

by Delcath Systems | Nov 2, 2026 | Community

Every November, National Family Caregivers Month invites us to pause and recognize the people who carry so much of a patient’s journey alongside them. At Delcath, we want to take this moment to say something simple and sincere: thank you.

The care that happens beyond the clinic

A cancer diagnosis doesn’t happen to one person. It reaches spouses, parents, children, siblings, and friends, who often become caregivers overnight, without a manual or much time to prepare.

One patient living with metastatic uveal melanoma put it plainly: “There is no instruction manual for this for any of us.”

Behind every appointment is someone who rearranged their work schedule. Behind every treatment day is someone who traveled, waited, took notes, and asked the questions the patient was too overwhelmed to ask. One wife described making sure everything at home was in place so she could travel with her husband and be fully present: “We prayed, we did checklists, so that he could just focus on his recovery and I could focus on helping him recover.”

Her husband, a patient, was just as clear about what her presence meant: “Without her, I probably wouldn’t have done a second [treatment].” And on having someone willing to do anything for you, he said, “It’s very special, and I hope everyone gets to experience it.”

“There is no instruction manual for this for any of us.”

— Patient living with metastatic uveal melanoma

Caregivers need care, too

Caregiving is demanding, and the people doing it are human. The same wife described how she recharged: a walk, a good cry in the shower, a long talk with her best friend. Afterward, she said, “I’m replenished and I kind of filled my cup so that I can be strong for him again.”

A mother who cared for her adult daughter learned that setting boundaries was part of caring well. Her message to other caregivers is one we’d like everyone to hear: “You are a good caregiver… what you’re doing, it is enough.” And she added a reminder that applies to all of us: “No one in any big hard life journey has to do it alone.”

Her daughter, a patient, had her own words for the person who stood by her: “Thank you for crawling into the pit with me, sitting with me when I don’t want to climb out, and then helping me claw my way back to the surface to find a little bit of that hope.”

The whole care team matters

Caregiving extends beyond family. Patients with disease in their liver depend on a wider circle: oncologists, interventional radiologists, anesthesiologists, nurses, pharmacists, perfusionists, technologists, social workers, patient navigators, and the administrative staff who answer the phone when someone is anxious.

For many families, those teams become part of the story. As one caregiver said of the clinical staff who cared for her husband, “They became family because it was the same staff, the same nurses, the same doctors every single time that we were there.”

One patient remembers a nurse who noticed how distraught she was at one of the hardest moments of her hospital stay and quietly took her hand, gripping it tightly until she felt steadier. Another patient and his wife marked their later treatment visits by bringing cookies to the clinic staff, a small way of saying thanks to the people who had become so familiar.

Patients look after one another, too. One patient recalled meeting a fellow patient just days after that person’s own treatment, and thinking, “If she can be here then, I can do this.”

A few ways to support a caregiver this month

If you know a caregiver, November is a good time to remind them they’re seen. Small gestures often mean the most:

  • Offer specific help, like a meal, a ride, or an hour of company, rather than “let me know if you need anything.”
  • Check in on the caregiver, not just the patient.
  • Encourage them to rest without guilt. Caring for themselves is part of caring for someone else.
  • Simply say thank you.

To every caregiver and care team member

You are the steady presence in some of the hardest moments of someone’s life. As one caregiver told us, “As long as you are there and you show up, it’s a blessing to be there every step of the way.”

We are deeply grateful for all you do, this month and every month.

Thank you for showing up.

Stay Connected

Follow Delcath for more patient education, company updates and perspectives from the oncology community.

Get more information from our dedicated team revolutionizing the treatment of patients with cancers of the liver.

Contact Us

Connect with Us

Email LinkedIn YouTube X

Copyright © 2026 Delcath Systems, Inc. All rights reserved.

**Privacy Policy   |  Terms of Use  |  Accessibility **

This website uses cookies

This website uses cookies to improve user experience. By using our website you consent to all cookies in accordance with our Cookie Policy. Read more

 Privacy Policy

Strictly necessary

Performance

Targeting

Functionality

Accept allDecline allShow details

by Delcath Systems

| Oct 22, 2026 | Events

Clinicians know how much happens outside the exam room: the questions that surface in the parking lot, the worries that don’t make it into the visit, the caregiver quietly carrying more than anyone sees. For one weekend in Dallas, the Eye Believe Survivorship Seminar brought patients, caregivers, and physicians together with room to talk about all of it.

Hosted by A Cure In Sight (ACIS) at the University of Texas Southwestern Medical Center (UTSW) an independent nonprofit that has served the ocular melanoma community for more than a decade, the seminar is described by the organization as one of the few nationwide events dedicated exclusively to people living with ocular melanoma.

A Diagnosis that Leaves People Searching

Uveal melanoma is rare, and for many patients a diagnosis means isolation as well as fear. Few people in their lives have heard of it, and many aren’t sure where to turn next.

That is why ACIS founder and president Melody Burchett says the seminar matters so much:

“The Eye Believe Survivorship Seminar is meaningful to me because no patient or family should have to face ocular melanoma feeling alone or without answers. Patient symposiums bring people together with leading physicians, researchers, advocates, and—most importantly—one another. They provide trusted information, genuine connection, and renewed hope. When patients feel informed, supported, and heard, they become empowered partners in their care and in shaping a better future for everyone affected by this disease.”

— Melody Burchett, Founder and President, A Cure In Sight

The seminar, held October 1 to 3, 2026, at the Marriott Suites Medical Market Center, was built around that idea. Patients and caregivers came for connection as much as for the clinical updates.

More than a Medical Conference

Friday’s program centered on the parts of the journey that rarely fit into a clinic visit:

  • Caregiver Camp

  • “Finding Your Footing: Mental Health After Your Diagnosis”

  • “Working the System 2.0: Insurance, Advocacy and Financial Support”

  • Patient roundtables

A session called “Get to Know Your OMies” gave attendees time to meet others who share their experience.

The roundtables also offered a look at how patients find information, where they feel gaps remain, and how factors like travel, cost, and access shape their experience.

Physicians in the Room

Saturday’s clinical program was presented by uveal melanoma specialists, including Dr. William Harbour, Dr. Sanjay Chandrasekaran, Dr. Alex Shoushtari, Dr. Udai Kammula, and Dr. Sunandana Chandra, among others. Sessions covered topics from early disease and diagnostics to treatment strategy and ongoing research.

Beyond the presentations, what stood out was the time physicians spent in conversation with attendees, answering questions and listening.

Seeing Where the Research Happens

Attendees also toured the Harbour Lab in two sessions on Friday afternoon, a chance to see where research takes place and to meet the people behind it.

A Look Behind the Scenes

For many patients, the unknown is the hardest part of what’s ahead, including the portions of care they won’t be awake for. On Friday evening, attendees joined a procedure demonstration at UT Southwestern, moving through stations where members of the care team showed the work they do during the procedure.

What Patients Shared

Across sessions, a few themes came up repeatedly: the value of clear information, the comfort of being among people who understand, and the role caregivers play.

The Takeaway

Support extends beyond the clinic. Patients, caregivers, advocates, and healthcare professionals each play a part in helping people through this journey. In Dallas, that was easy to see.

Learn more about the Eye Believe Survivorship Seminar and A Cure In Sight at acureinsight.org/education-events

Prompts

Delcath Systems, Inc. (ticker DCTH), listed in United States.

ETFs Holding Delcath Systems, Inc.

ETF Weight in ETF Shares Market value As of
SURI 5.92% 207,999 $ 4.029M Nov 17, 2026
AFSM 0.14% 10,646 $ 211.536K Nov 16, 2026
AVSC 0.03% 47,518 $ 944.183K Nov 16, 2026
DFAS 0.01% 120,614 $ 2.579M Nov 12, 2026
DFSU 0.00% 3,297 $ 70.49K Nov 12, 2026
DCOR 0.00% 29,361 $ 627.738K Nov 12, 2026
DFAC 0.00% 49,254 $ 1.053M Nov 12, 2026
DFUS 0.00% 4,020 $ 85.948K Nov 12, 2026